PURPOSE: We aimed to investigate the prognostic factors that can predict terminal stage survival (TSS) at the time of terminal cancer diagnosis. METHODS: We prospectively evaluated 141 patients immediately after the diagnosis of terminal cancer by their attending oncologists. A total of 32 factors, including performance status, clinical prediction of survival, time to terminal cancer (TTC), clinical symptoms, signs, and laboratory tests including the neutrophil-lymphocyte ratio (NLR), were analyzed. TSS was defined as the time from the diagnosis of terminal cancer to death. RESULTS: The mean age of the 141 patients studied was 58.7 years, and 53 were female (38 %). The median TSS was 1.7 months (95 % confidence interval [CI] 1.43-1.97). In the univariate analyses, the TSS was significantly associated with 16 of the 32 factors tested. In the multivariate analysis, a lower Karnofsky performance status (KPS), a shorter TTC (<24 months), a high NLR (≥5), and a high C-reactive protein (CRP) level (≥10 mg/dL) were independently associated with a poorer prognosis. A scoring system (scale, 0-6) developed based on the multivariate analysis could be used to classify terminal cancer patients into better (0-2 points; TSS 3.9 months), intermediate (3-4 points; TSS 1.7 months), or worse (5-6 points; TSS 0.9 month, P < 0.001) prognosis. CONCLUSION: The median TSS after the diagnosis of terminal cancer in advanced cancer patients was 1.7 months. The scoring system using KPS, TTC, NLR, and CRP could predict TSS in these patients.
PURPOSE: We aimed to investigate the prognostic factors that can predict terminal stage survival (TSS) at the time of terminal cancer diagnosis. METHODS: We prospectively evaluated 141 patients immediately after the diagnosis of terminal cancer by their attending oncologists. A total of 32 factors, including performance status, clinical prediction of survival, time to terminal cancer (TTC), clinical symptoms, signs, and laboratory tests including the neutrophil-lymphocyte ratio (NLR), were analyzed. TSS was defined as the time from the diagnosis of terminal cancer to death. RESULTS: The mean age of the 141 patients studied was 58.7 years, and 53 were female (38 %). The median TSS was 1.7 months (95 % confidence interval [CI] 1.43-1.97). In the univariate analyses, the TSS was significantly associated with 16 of the 32 factors tested. In the multivariate analysis, a lower Karnofsky performance status (KPS), a shorter TTC (<24 months), a high NLR (≥5), and a high C-reactive protein (CRP) level (≥10 mg/dL) were independently associated with a poorer prognosis. A scoring system (scale, 0-6) developed based on the multivariate analysis could be used to classify terminal cancerpatients into better (0-2 points; TSS 3.9 months), intermediate (3-4 points; TSS 1.7 months), or worse (5-6 points; TSS 0.9 month, P < 0.001) prognosis. CONCLUSION: The median TSS after the diagnosis of terminal cancer in advanced cancerpatients was 1.7 months. The scoring system using KPS, TTC, NLR, and CRP could predict TSS in these patients.
Authors: Young Ho Yun; Myung Kyung Lee; Seon Young Kim; Woo Jin Lee; Kyung Hae Jung; Young Rok Do; Samyong Kim; Dae Seog Heo; Jong Soo Choi; Sang Yoon Park; Hyun Sik Jeong; Jung Hun Kang; Si-Young Kim; Jungsil Ro; Jung Lim Lee; Sook Ryun Park; Sohee Park Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544
Authors: M Pirovano; M Maltoni; O Nanni; M Marinari; M Indelli; G Zaninetta; V Petrella; S Barni; E Zecca; E Scarpi; R Labianca; D Amadori; G Luporini Journal: J Pain Symptom Manage Date: 1999-04 Impact factor: 3.612
Authors: Jaime Feliu; Ana María Jiménez-Gordo; Rosario Madero; José Ramón Rodríguez-Aizcorbe; Enrique Espinosa; Javier Castro; Jesús Domingo Acedo; Beatriz Martínez; Alberto Alonso-Babarro; Raquel Molina; Juan Carlos Cámara; María Luisa García-Paredes; Manuel González-Barón Journal: J Natl Cancer Inst Date: 2011-10-04 Impact factor: 13.506
Authors: Bridget Gwilliam; Vaughan Keeley; Chris Todd; Matthew Gittins; Chris Roberts; Laura Kelly; Stephen Barclay; Patrick C Stone Journal: BMJ Date: 2011-08-25
Authors: Jason W Boland; Victoria Allgar; Elaine G Boland; Mike I Bennett; Stein Kaasa; Marianne Jensen Hjermstad; Miriam Johnson Journal: Eur J Clin Pharmacol Date: 2019-12-21 Impact factor: 2.953